405000.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 1.64, indicating a relatively high reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.1, suggesting limited short-term liquidity cushion. The company's price-to-book ratio is 3.72, and the price-to-tangible-book ratio is also 3.72, indicating that the market is valuing the company's equity at a premium relative to its book value. However, the enterprise value to EBITDA ratio is negative at -5.10, reflecting the company's current operating losses.

Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 6,586.9 billion KRW, with a return on equity of -1.15 and a return on assets of -0.32. These figures are well below the typical performance of firms in the medical equipment and supplies industry, which usually exhibit positive returns and higher margins. The operating loss of 5,248.8 billion KRW further underscores the company's current financial distress.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment-specific revenue data limits the ability to assess the performance of individual business lines.

The company's growth trajectory is negative, with a free cash flow of -5,559.3 billion KRW and an operating cash flow of -4,521.8 billion KRW. These figures indicate a lack of cash generation and a potential need for external financing. The capital expenditure of -279.4 billion KRW suggests minimal investment in long-term growth, further constraining future expansion.

Risk factors include a medium liquidity risk, driven by a current ratio of 1.1 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's operating losses and negative cash flows may necessitate future equity or debt financing, which could introduce dilution pressure.

Recent events include the filing of financial statements that reveal significant operating and net losses. No recent earnings call transcripts or major regulatory filings have been disclosed that would indicate strategic shifts or operational improvements. The company's financial performance remains a key concern for investors and stakeholders.